Immunological and molecular characteisitics of chronic myeloid leukemia patients after stopping imatinib
2018/31/B/NZ6/03361
Keywords
Descriptors
- NZ6_2: Immunologia kliniczna
- NZ5_3: Patogeneza chorób człowieka
- NZ5_7: Leczenie chorób człowieka
Panel
NZ6 – Human and animal immunology and infection: immunity, immune disorders, immunotherapy, infectious and invasive diseases, microbiology, transplantology, allergology
Host institution
Uniwersytet Medyczny w Lublinie, Wydział Lekarski
Voivodeship: lubelskie
Principal investigator (from the host institution)
Number of co-investigators in the project: 5
Call
OPUS 16 – announced on 2018-09-14
- Amount awarded
- 1 135 680 PLN
- Project start date
- 2019-07-22
- Project end date
- 2023-07-21
- Project duration
- 48 months (the same as in the proposal)
- Project status
- Project settled
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
Publication in academic press/journals (3)
-
High Level of CD8+PD-1+ Cells in Patients with Chronic Myeloid Leukemia Who Experienced Loss of MMR after Imatinib Discontinuation
- Authors:
- Paulina Kwaśnik, Joanna Zaleska, Dorota Link-Lenczowska, Magdalena Zawada, Hubert Wysogl, Bogdan Ochrem, Grażyna Bober, Ewa Wasilewska, Iwona Hus, Monika Szarejko, Witold Prejzner, Olga Grzybowska-Izydorczyk, Agnieszka Klonowska- Szymczyk, Ewa Mędraś, Michał Kiełbus,Tomasz Sacha and Krzysztof Giannopoulos
- Academic press:
- Cells (year: 2024, volume: 13(8), pages: 723), Publisher: MDPI
- Status:
- Published
- DOI:
- 10.3390/cells13080723 – link to the publication
-
Treatment-free remission - a new aim in the treatment of chronic myeloid leukemia
- Authors:
- Paulina Kwaśnik, Krzysztof Giannopoulos
- Academic press:
- Journal of Personalized Medicine (year: 2021, volume: 11(8), 697, pages: 46047), Publisher: MDPI
- Status:
- Published
- DOI:
- 10.3390/jpm11080697 – link to the publication
-
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib.
- Authors:
- Machova Polakova K, Albeer A, Polivkova V, Krutska M, Vlcanova K, Curik N, Fabarius A, Klamova H, Spiess B, Waller CF, Brümmendorf TH, Dengler J, Kunzmann V, Burchert A, Belohlavkova P, Mustjoki S, Faber E, Mayer J, Zackova D, Panayiotidis P, Richter J, Hjorth-Hansen H, Kamińska M, Płonka M, Szczepanek E, Szarejko M, Bober G, Hus I, Grzybowska-Izydorczyk O, Wasilewska E, Paczkowska E, Niesiobędzka-Krężel J, Giannopoulos K, Mahon FX, Sacha T, Saußele S, Pfirrmann M.
- Academic press:
- Leukemia (year: 2024, volume: 38(2), pages: 318-325), Publisher: Nature Publishing Group
- Status:
- Published
- DOI:
- 10.1038/s41375-023-02109-2 – link to the publication
Articles in post-conference publications (1)
-
IMMUNE FACTORS MAINTAINING TREATMENT-FREE REMISSION IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA AFTER DISCONTINUATION OF IMATINIB
- Authors:
- Kwaśnik, P.; Zaleska, J.; Link-Lenczowska, D.; Zawada, M.; Ochrem, B.; Bober, G.; Wasilewska, E.; Mędraś, E.; Hus, I.; Szarejko, M.; Prejzner, W.; Grzybowska-Izydorczyk, O.; Klonowska-Szymczyk, A; Sacha, T.; Giannopoulos, K
- Conference:
- European Haematology Association (year: 2022, pages: 587-588), Publisher: Wolters Kluwer Health
- Date:
- conference 6,2022
- Status:
- Published
- DOI:
- link to the publication